# Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

> **NCT03430089** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 101 (actual)

## Conditions studied

- Influenza
- Flu

## Interventions

- **BIOLOGICAL:** Shz QIV 0.25 mL, 2 doses
- **BIOLOGICAL:** Shz QIV 0.5 mL, 2 doses
- **BIOLOGICAL:** Shz QIV 0.5 mL, single dose

## Key facts

- **NCT ID:** NCT03430089
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-22
- **Primary completion:** 2019-06-06
- **Final completion:** 2019-06-06
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430089, "Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03430089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*